Article
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Cancer science - 1 Oct 2018
Sato Hiroki, Yamamoto Hiromasa, Sakaguchi Masakiyo, Shien Kazuhiko, Tomida Shuta, Shien Tadahiko, Ikeda Hirokuni, Hatono Minami, Torigoe Hidejiro, Namba Kei, Yoshioka Takahiro, Kurihara Eisuke, Ogoshi Yusuke, Takahashi Yuta, Soh Junichi, Toyooka Shinichi
Abstract excerpt
Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non-small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide-3 kinase (PI3K) pathways for acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC. We investigated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.